AEterna Zentaris (AEterna Zentaris) Accounts Payable & Accrued Expense : $3.39 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Accounts Payable & Accrued Expense?

AEterna Zentaris's quarterly accounts payable & accrued expense declined from Jun. 2023 ($3.68 Mil) to Sep. 2023 ($3.41 Mil) and declined from Sep. 2023 ($3.41 Mil) to Dec. 2023 ($3.39 Mil).

AEterna Zentaris's annual accounts payable & accrued expense increased from Dec. 2021 ($2.25 Mil) to Dec. 2022 ($3.61 Mil) but then declined from Dec. 2022 ($3.61 Mil) to Dec. 2023 ($3.39 Mil).

AEterna Zentaris Accounts Payable & Accrued Expense Historical Data

The historical data trend for AEterna Zentaris's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Accounts Payable & Accrued Expense Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

3.17

2.32

2.25

3.61

3.39

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															3.61	4.24	3.68	3.41	3.39

AEterna Zentaris Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.